• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

47.64 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 515
Open 47.64
Bid (Size) 47.34 (100)
Ask (Size) 48.02 (100)
Prev. Close 47.64
Today's Range 47.64 - 47.64
52wk Range 44.12 - 78.48
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Mid-Cap Growth Stocks With Monstrous Long-Term Upside ↗
July 28, 2026
These stocks have market caps below $5 billion, but they could be much more valuable in the future. 
Via The Motley Fool
News headline image
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating ↗
July 22, 2026
This particular position isn't rooted solely in the science you've heard most about from the biopharma company so far. 
Via The Motley Fool
Topics ETFs

Performance

YTD
-11.4%
-11.4%
1 Month
-15.5%
-15.5%
3 Month
-6.1%
-6.1%
6 Month
-11.3%
-11.3%
1 Year
-19.3%
-19.3%

More News

Read More
News headline image
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? ↗
July 20, 2026
Via The Motley Fool
News headline image
3 Reasons to Buy CRISPR Therapeutics Stock ↗
July 10, 2026
Via The Motley Fool
News headline image
Vertex’s Crinetics Deal Balances Growth with Integration Risk ↗
July 08, 2026
Via MarketBeat
News headline image
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics ↗
July 08, 2026
Via The Motley Fool
News headline image
Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now ↗
July 07, 2026
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? ↗
July 07, 2026
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
July 06, 2026
Via The Motley Fool
News headline image
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
June 27, 2026
Via The Motley Fool
News headline image
The Best Stocks to Invest $1,000 in Right Now ↗
June 22, 2026
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year ↗
June 18, 2026
Via The Motley Fool
News headline image
The Best Biotech Stocks to Buy in 2026 ↗
June 17, 2026
Via The Motley Fool
Topics ETFs
News headline image
Here's How I'd Invest $10,000 Right Now ↗
June 17, 2026
Via The Motley Fool
News headline image
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? ↗
June 08, 2026
Via The Motley Fool
News headline image
CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential ↗
June 03, 2026
Via The Motley Fool
News headline image
Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out ↗
June 03, 2026
Via The Motley Fool
News headline image
CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking ↗
June 01, 2026
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? ↗
May 31, 2026
Via The Motley Fool
News headline image
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗
May 25, 2026
Via The Motley Fool
News headline image
The Best Stocks to Invest $3,000 In Right Now ↗
May 19, 2026
Via The Motley Fool
News headline image
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms ↗
May 15, 2026
Via MarketBeat
Topics Intellectual Property
News headline image
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? ↗
May 11, 2026
Via The Motley Fool
News headline image
Is This Millionaire-Maker Biotech Stock a Buy Right Now? ↗
May 06, 2026
Via The Motley Fool
Topics Initial Public Offering
News headline image
Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering ↗
April 30, 2026
Via The Motley Fool

Frequently Asked Questions

Is CRISPR Therapeutics AG - Common Shares publicly traded?
Yes, CRISPR Therapeutics AG - Common Shares is publicly traded.
What exchange does CRISPR Therapeutics AG - Common Shares trade on?
CRISPR Therapeutics AG - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for CRISPR Therapeutics AG - Common Shares?
The ticker symbol for CRISPR Therapeutics AG - Common Shares is CRSP on the Nasdaq Stock Market
What is the current price of CRISPR Therapeutics AG - Common Shares?
The current price of CRISPR Therapeutics AG - Common Shares is 47.64
When was CRISPR Therapeutics AG - Common Shares last traded?
The last trade of CRISPR Therapeutics AG - Common Shares was at 07/29/26 04:00 PM ET
What is the market capitalization of CRISPR Therapeutics AG - Common Shares?
The market capitalization of CRISPR Therapeutics AG - Common Shares is 3.76B
How many shares of CRISPR Therapeutics AG - Common Shares are outstanding?
CRISPR Therapeutics AG - Common Shares has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap